Cost Per Response Analysis of Nivolumab Versus Everolimus in the Treatment of Patients Previously Treated with Advanced Renal Cell Carcinoma – Brazil Private Health Care System Perspective
Abstract
Authors
L Brust G Bernardino G Aratangy S Tanaka L Paladini L Borges OA Clark